NDLI: Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy

Please wait, while we are loading the content...

Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy

Content Provider	Scilit
Author	Furusawa, Aki Reiser, John Sadashivaiah, Kavitha Simpson, Haley Banerjee, Arnob
Copyright Year	2018
Description	Journal: Journal of Immunotherapy Tumor-specific CD8+ T cells often fail to elicit effective antitumor immune responses due to an inability to expand into a substantial effector population and persist long-term in vivo. Using an adoptive transfer model of cancer immunotherapy, we demonstrate that constitutive eomesodermin (Eomes) expression in tumor-specific CD8+ T cells improves tumor rejection and survival. The increase in tumor rejection was associated with an increased number and persistence of CD8+ T cells in lymphoid tissues during acute tumor rejection, tumor regrowth, and in mice that remained tumor-free. Constitutive Eomes expression increased expression of CD25, and this was associated with enhanced interleukin-2 responsiveness and tumor-specific CD8+ T-cell proliferation. Moreover, constitutive Eomes expression improved cell survival. Taken together, our data suggest that constitutive Eomes expression enhances CD8+ T-cell proliferation and survival, in part through the enhancement of interleukin-2 responsiveness through CD25 induction.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801069/pdf
Ending Page	63
Page Count	11
Starting Page	53
ISSN	15249557
e-ISSN	15374513
DOI	10.1097/cji.0000000000000206
Journal	Journal of Immunotherapy
Issue Number	2
Volume Number	41
Language	English
Publisher	Ovid Technologies (Wolters Kluwer Health)
Publisher Date	2018-02-01
Access Restriction	Open
Subject Keyword	Journal: Journal of Immunotherapy Cell Tissue Engineering Cd8+ T Cells, Eomesodermin, Adoptive Transfer Immunotherapy, Cd25, Interleukin-2, Antitumor Immune Response
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Cancer Research Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8⁺ T cells.

Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth

CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2

The Journal of Immunology CD8 � T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4 � T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T Cells

Harnessing the IL-21-BATF Pathway in the $CD8^{+}$ T Cell Anti-Tumor Response

Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?

Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy

Similar Documents

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells.

Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth

CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2

The Journal of Immunology CD8 � T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4 � T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T Cells

Harnessing the IL-21-BATF Pathway in the $CD8^{+}$ T Cell Anti-Tumor Response

Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?

Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8⁺ T cells.